Compare DexCom, Inc. (DXCM) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Schwab US Large Cap Growth ETF — how do they compare? DexCom, Inc. trades at $90.56 (market cap $33.79B), while Schwab US Large Cap Growth ETF trades at $35.65. Which is the better fit depends on your goals.
| DXCM | SCHG | |
|---|---|---|
Market Cap | $33.79B | — |
Sector | Health | Sector/Thematic |
52-Week High | $89.53 | $35.83 |
52-Week Low | $54.84 | $28.10 |
Enterprise Value | $33.24B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $90.23, up 2.94% today and near its 52-week high, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.70 versus $0.61 expected, and raised full-year guidance. Revenue growth remains robust at 13% year-over-year, supported by G7 system adoption and international expansion. Profit margins improved, with net income margin reaching 20.12% in 2025. Analyst sentiment is overwhelmingly positive, with 80% buy ratings.
The outlook for DXCM is favorable due to sustained demand for continuous glucose monitors and strategic initiatives like 'Road to 100'. Key risks include competitive pressures, regulatory scrutiny, and valuation multiples above industry averages. The stock's current price is slightly above the consensus target of $88.65, suggesting near-term consolidation may occur before further upside.
SCHG trades at $35.62, down 0.59% today, with a bullish technical outlook supported by moving averages. The ETF's concentrated portfolio of large-cap growth stocks, particularly in technology, drives performance but introduces concentration risk. Recent news highlights strong historical returns and institutional activity, though some analysts question current valuations.
Outlook remains positive given exposure to AI and technology growth trends, but investors face risks from high concentration in top holdings and sensitivity to interest rate changes. The low 0.04% expense ratio and tax efficiency are key advantages for long-term growth investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →
